AORT
Artivion, Inc.
Artivion (AORT) Q2 2026 earnings
Published Aug 6, 2026
AI summary
- Revenue $126M, up 11% from $113M a year ago.
- Adjusted EPS $0.13 beat the $0.10 consensus by $0.03, down from $0.24 a year ago.
- Artivion reported second quarter 2026 revenue of $125.8 million, an 11% increase over the prior year.
- The company recorded a GAAP net loss of $13.5 million, while non-GAAP net income was $6.3 million.
- Growth was primarily driven by strong performance in the On-X and stent graft product lines.
Results vs analyst consensus
Revenue
Reported
$126M
Consensus not captured before release
+11% YoY
Adjusted EPS
Reported · non-GAAP net income
$0.13
Consensus $0.10
Beat by $0.03GAAP EPS: −$0.28
Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.
Next quarter outlook
$480M–$496M
full year 2026 revenue guidance
Next-quarter consensus not captured before release.
What to watch
- The company reported a GAAP net loss of $13.5 million for the quarter.
- Results include $0.7 million in pretax losses related to foreign currency revaluation.
Read original report
Source: Artivion, Inc. press release · SEC Form 8-K exhibit 99.1